Clinical trial
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
NCT01779206
Study timeline
Study start (actual)2012-05-01Date precision: month
Registry last updated2025-04-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
EpirubicinDRUG · verified · RxNorm: epirubicin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
DocetaxelDRUG · verified · RxNorm: docetaxel
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Women's Cancer Study Group GmbHlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01779206 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.